Physician profile
James M Fernandez
NPI 1649495003
$179,277.58
in general payments reported to CMS, 2019-2025
8 companies · $35K in 2025
The $35K reported for 2025 was more than what 94% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,655 · 2020: $10K · 2021: $20K · 2022: $21K · 2023: $12K · 2024: $74K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $87K · Travel and Lodging: $16K · Consulting Fee: $16K · Food and Beverage: $2,623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $86,688.50 |
| Travel and Lodging | $16,371.43 |
| Consulting Fee | $15,604.50 |
| Food and Beverage | $2,623.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $153,571.26 | 2020-2025 | Hyqvia, Cuvitru |
| Merck Sharp & Dohme LLC | $10,180.00 | 2019-2025 | |
| Shire North American Group INC | $5,725.38 | 2019 | |
| Genzyme Corporation | $5,164.52 | 2025 | |
| Genentech USA, INC. | $2,645.00 | 2020 | |
| Invivyd INC | $1,750.00 | 2025 | Pemgarda |
| Amgen INC. | $142.50 | 2025 | Uplizna |
| Novartis Pharmaceuticals Corporation | $98.92 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Fernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.